Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: A report from the Japanese pediatric leukemia/lymphoma study group

Blood Cancer Journal

Volumn 4, Issue 7, 2014, Pages

  Matsuo, H ^a   Kajihara, M ^a   Tomizawa, D ^b   Watanabe, T ^c   Saito, A M ^d   Fujimoto, J ^e   Horibe, K ^d   Kodama, K ^a   Tokumasu, M ^a   Itoh, H ^a   Nakayama, H ^f   Kinoshita, A ^g   Taga, T ^h   Tawa, A ⁱ   Taki, T ^j   Tanaka, S ^a   Adachi, S ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PROGNOSIS; CEBPA GENE; CHILD; CYTOGENETICS; DNA POLYMORPHISM; EVENT FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; HUMAN; JAPANESE (PEOPLE); KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; INFANT; MULTICENTER STUDY; MUTATION; PRESCHOOL CHILD; PROGNOSIS;

CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN;

ADOLESCENT; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84905367271     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.47     Document Type: Article

References (27)

1. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519.
2. Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen L et al. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell 2001; 107: 247-258.
3. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol 2001; 21: 3789-3806.
4. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005; 19: 329-334.
5. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394-400.
6. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
7. Asou H, Gombart AF, Takeuchi S, Tanaka H, Tanioka M, Matsui H et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 2003; 36: 167-174.
8. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
9. Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100: 1343-1346.
10. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
11. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28: 570-577.
12. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28: 2739-2747.
13. Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 2013; 28: 794-803.
14. Liang DC, Shih LY, Huang CF, Hung IJ, Yang CP, Liu HC et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia 2005; 19: 410-414.
15. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113: 6558-6566.
16. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011; 96: 384-392.
17. Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood 2011; 118: 5905-5913.
18. Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H et al. Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol 2010; 91: 831-837.
19. Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T et al. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia 2013; 27: 2413-2416.
20. Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T et al. Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 2013; 98: 578-588.
21. Wouters BJ, Louwers I, Valk PJ, Löwenberg B, Delwel R. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 2007; 109: 389-390.
22. Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C et al. Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 2008; 22: 655-657.
23. Kim S, Kim DH, Jang JH, Jung CW, Jang MA, Ki CS et al. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. Ann Lab Med 2012; 32: 153-157.
24. Bereshchenko O, Mancini E, Moore S, Bilbao D, Mansson R, Luc S et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 2009; 16: 390-400.
25. Somervaille TC, Cleary ML. Preview. Mutant CEBPA: priming stem cells for myeloid leukemogenesis. Cell Stem Cell 2009; 5: 453-454.
26. Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol 2012; 91: 1051-1063.
27. Park SH, Chi HS, Cho YU, Jang S, Park CJ. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Leuk Res 2013; 37: 1488-1494.